Mesothelioma Treatment
Mesothelioma Cancer
- Causes of Mesothelioma
- Mesothelioma Symptoms
- Mesothelioma Diagnosis
- Mesothelioma Stages
- Mesothelioma Treatment
- Innovative Mesothelioma Treatments
- Managing Mesothelioma Pain
- Nutrition Information for Mesothelioma Patients
- Specialized Mesothelioma Care
- Mesothelioma Risks
- Mesothelioma Support Groups
- Find a Mesothelioma Attorney
- Mesothelioma News
Mesothelioma Directory
Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy
Get Help Today
Looking for help or additional information? Contact us today.| Conditions: | Malignant Pleural Mesothelioma |
| Start Date: | December 1, 2010 |
| Phase: | Phase II |
| Status: | Recruiting |
| NCT ID: | NCT01265433 |
| Study Type: | Interventional |
| Intervention: | Biological: WT-1-vaccine Montanide + GM-CSF|Biological: Montanide adjuvant + GM-CSF |
| Study Design: | Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | Memorial Sloan-Kettering Cancer Center|Department of Defense |
| Ages: | Adult|Senior |
| Enrollment: | 78 |
| Funded By: | Other|U.S. Fed |
| First Received: | December 21, 2010 |
| End Date: | December 1, 2014 |
| Last Updated: | December 22, 2010 |
| Last Verified: | December 1, 2010 |